The EndoCannabinoid System (ECS) is involved in a host of bodily functions, including reducing pain and inflammation. The specific roles of currently identified endocannabinoids that act as smaller molecules attaching to larger molecules at cannabinoid receptors within the central nervous system (primarily but not exclusively CB1 receptors) and in the periphery (primarily but not exclusively CB2 receptors) are only partially explained, but they do influence the nervous system.
Plant-based PhytoCannabinoid Rich Cannabidiol (CBD) Oil and chemically related compounds, like the terpenes, commonly found in many foods, have been found to have significant analgesic (pain reducing) effects on various chronic pain conditions.
However, other phytocannabinoids in combination, especially cannabidiol and β-caryophyllene, (like in Botany Bay Oils PCRx Plus and PCRx ULTRA) delivered by the oral route appear to be promising candidates for the treatment of chronic pain due to their high safety and low adverse effects.
This paper published by Rambam Maimonides Medical Journal and by the Medical Library of the National Institutes of Health discusses the foundational basic and clinical science linking the endocannabinoid system and the phytocannabinoids and their role in the management of chronic pain.